Azenta, a provider of life sciences services including genomics, cryogenic storage, automation, and informatics, has announced changes to its board in return for a commitment from activist investor Politan Capital Management not to push for seats, according to a report by Reuters.
The announcement came as the company also revealed strong earnings, with shares jumping by nearly 12% in after-hours trading on Monday as a result.
As part of the deal, two new directors will join the board while two current directors will retire, the company said, adding that it will make an additional $500m in share repurchases in fiscal 2024 and will focus on "smaller tuck-in acquisitions."
In return, Politan, which is one of the company's biggest shareholders with a 7.5% stake, withdrew its notice to nominate director candidates for election, which was seen as a precursor to a possible proxy fight.
The report cites unnamed sources with knowledge of the mater as revealing that Azenta and Politan have held a series of private discussions to find ways of increasing shareholder value.
Yen carry trade risks mount
Hedge funds and other leveraged investors face renewed risks from the yen carry trade as Japan moves further away from decades of…
More
Valour launches first crypto hedge fund using Neuronomics AI strategy
Valour, the digital asset investment products subsidiary of DeFi Technologies, has launched its first hedge fund as it expands beyond…
More
SocGen targets strong prime brokerage growth
Societe Generale is planning to significantly expand its prime brokerage business as part of Chief Executive Officer Slawomir Krupa's…
More